Search results
Perioperative Nivolumab Boosts EFS in Resectable Lung Cancer
MedPage Today· 2 days agoCheckMate 77T trial shows 42% reduction in risk of tumor recurrence, progression, or death
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Zacks via Yahoo Finance· 2 hours agoThe study evaluated Opdivo (nivolumab) with concurrent chemoradiotherapy (CCRT) followed by Opdivo...
Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer, Phase...
Medical Xpress· 2 days agoAt a median follow-up of 25.4 months, the median EFS with chemotherapy alone was 18.4 months, while...
BMS reports four-year data from psoriasis treatment extension trial
Clinical Trials Arena via Yahoo Finance· 6 hours ago“Our leadership in TYK2 innovation highlights our transformational science that is advancing care...
Immunotherapy may boost survival after lung cancer surgery
United Press International via Yahoo News· 22 hours agoImmunotherapy can boost the survival of early-stage lung cancer patients eligible for surgery when...
BMS Opdivo and Yervoy combo misses primary endpoint in Phase III NSCLC trial
Clinical Trials Arena via Yahoo Finance· 4 days agoBristol Myers Squibb’s (BMS) blockbuster cancer therapies Opdivo (nivolumab) and Yervoy (ipilimumab)...
Americans Are Spending the Most Money on These 25 Prescription Drugs
Healthline· 1 day agoThe diabetes and weight loss medication semaglutide (Ozempic, Wegovy, and Rybelsus) topped the list....
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
Zacks via Yahoo Finance· 4 days agoBristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails...
David Braun, MD, PhD, on Biomarkers in Renal Cell Carcinoma
MedPage Today· 4 days agoFor patients with metastatic renal cell carcinoma (RCC), there are as yet no reliable biomarkers to...